Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (311-320 of 361) with videos related to

Pageof 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2018
Clinical and Genomic Implications of Luminal and Basal Subtypes Across CarcinomasShuang G Zhao, William S Chen, Rajdeep Das, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2018
Phase I Study of CTT1057, an <sup>18</sup>F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate CancerSpencer C Behr, Rahul Aggarwal, Henry F VanBrocklin, et al.
The Journal of Clinical Investigation|October 1, 2024
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancerXiaolin Zhu, Tatyanah Farsh, Daniël Vis, et al.
Urologic Oncology|July 7, 2020
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancerDaniel H Kwon, Li Zhang, David A Quigley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2023
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)Michael J Morris, Glenn Heller, David W Hillman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate CancerXiangnan Guan, Duanchen Sun, Eric Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP InhibitorsJonathan Chou, Troy M Robinson, Emily A Egusa, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
Genome Biology|April 16, 2026
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancerThaidy Moreno-Rodriguez, Meng Zhang, Arian Lundberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Bladder cancerJames E Montie, Peter E Clark, Mario A Eisenberger, et al.
Pageof 37

Showing results (311-320 of 361) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2018
Clinical and Genomic Implications of Luminal and Basal Subtypes Across CarcinomasShuang G Zhao, William S Chen, Rajdeep Das, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2018
Phase I Study of CTT1057, an <sup>18</sup>F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate CancerSpencer C Behr, Rahul Aggarwal, Henry F VanBrocklin, et al.
The Journal of Clinical Investigation|October 1, 2024
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancerXiaolin Zhu, Tatyanah Farsh, Daniël Vis, et al.
Urologic Oncology|July 7, 2020
Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancerDaniel H Kwon, Li Zhang, David A Quigley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2023
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)Michael J Morris, Glenn Heller, David W Hillman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate CancerXiangnan Guan, Duanchen Sun, Eric Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP InhibitorsJonathan Chou, Troy M Robinson, Emily A Egusa, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
Genome Biology|April 16, 2026
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancerThaidy Moreno-Rodriguez, Meng Zhang, Arian Lundberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Bladder cancerJames E Montie, Peter E Clark, Mario A Eisenberger, et al.
Pageof 37